References
- Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072–81.
- Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69: 631–7.
- Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology. 2010;49:2154–64.
- Miyasaka N. CHANGE Study Investigators. Clinical investiga-tion in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
- Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum. 2003;48:35–45.
- Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.
- Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneu-mocystis pneumonia. Chest. 2007;131:1173–80.
- Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol. 2006;16:251–5.
- Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K, et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res. 2000;6: 4069–72.
- Kawata T, Tsukagoshi H, Mashimo T, Kakizaki S, Kasahara T, Iwasaki J, et al. KL-6-producing invasive thymoma. Intern Med. 2002;41:979–82.
- Gad A, Tanaka E, Matsumoto A, Wahab MA, Ael-H Serwah, Attia F, et al. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World J Gastroenterol. 2005; 14(11):6607–12.
- Kida Y, Maeshima E, Furukawa K, Ichikawa T, Goda M, Ichi-nose M. A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol. 2007;17: 262–4.
- Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusion using novel monoclonal antibodies, KL-3 and KL-6 antigen against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18:203–16.
- Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96: 68–73.
- Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108:311–5.
- Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest. 1992;101:858–60.
- Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest. 1996;109: 1276–82.
- Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152:1860–6.